Related Experiment Video
Updated: May 19, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
[How to treat systemic necrotizing vasculitides?]
1AP-HP, hôpital Cochin, université Paris-Descartes, Sorbonne Paris Cité, service de médecine interne, Inserm 1016, 75014 Paris, France. loic.guillevin@cch.aphp.fr
Systemic necrotizing vasculitis treatments include corticosteroids and cytotoxic agents, aiming for remission. Maintenance therapy and newer biologics like rituximab help manage high relapse rates in this condition.
Area of Science:
- Rheumatology
- Immunology
Context:
- Systemic necrotizing vasculitides (SNVs) are serious autoimmune diseases.
- Treatment typically involves corticosteroids and cytotoxic agents for at least 18 months.
Purpose:
- To outline current treatment strategies for SNVs.
- To discuss remission rates, relapse, and maintenance therapies.
Summary:
- Corticosteroids and cytotoxic agents are standard SNV treatments.
- Remission is achieved in about 90% of patients, but relapse rates are high.
- Maintenance therapy (azathioprine, methotrexate) and biologics (rituximab) are crucial.
Impact:
- Provides an overview of SNV management.
- Highlights the importance of long-term treatment and newer therapeutic options like rituximab.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management